You just read:

Overall Use of Sanofi/Regeneron's Dupixent for the Treatment of Atopic Dermatitis in the EU5 Lags that of the US, Though Side Effects and Short-Term Use in Both Markets May be Cause for Concern

News provided by

Spherix Global Insights

Feb 27, 2019, 12:29 ET